Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sagimet Biosciences Inc Series A (SGMT)

Sagimet Biosciences Inc Series A (SGMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 175,944
  • Shares Outstanding, K 32,522
  • Annual Sales, $ 0 K
  • Annual Income, $ -45,570 K
  • EBIT $ -64 M
  • EBITDA $ -66 M
  • 60-Month Beta 3.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 108.26% (+0.92%)
  • Historical Volatility 77.87%
  • IV Percentile 47%
  • IV Rank 10.35%
  • IV High 322.38% on 01/28/26
  • IV Low 83.53% on 01/12/26
  • Expected Move (DTE 11) 0.85 (15.80%)
  • Put/Call Vol Ratio 0.10
  • Today's Volume 160
  • Volume Avg (30-Day) 407
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 14,336
  • Open Int (30-Day) 13,515
  • Expected Range 4.53 to 6.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.48
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +14.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.92 +9.35%
on 02/17/26
6.25 -13.92%
on 02/25/26
-0.07 (-1.28%)
since 02/09/26
3-Month
4.92 +9.35%
on 02/17/26
7.20 -25.28%
on 02/03/26
-0.90 (-14.33%)
since 12/09/25
52-Week
1.73 +210.98%
on 04/07/25
11.41 -52.85%
on 07/25/25
+1.70 (+46.20%)
since 03/07/25

Most Recent Stories

More News
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

SAN MATEO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference

SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications Collaboration...

SGMT : 5.38 (-0.55%)
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration

SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference

SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...

SGMT : 5.38 (-0.55%)
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567...

SGMT : 5.38 (-0.55%)

Business Summary

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel therapeutics targeting dysfunctional metabolic pathways. Sagimet Biosciences Inc. is based in SAN MATEO, Calif.

See More

Key Turning Points

3rd Resistance Point 5.81
2nd Resistance Point 5.61
1st Resistance Point 5.49
Last Price 5.38
1st Support Level 5.18
2nd Support Level 4.98
3rd Support Level 4.86

See More

52-Week High 11.41
Fibonacci 61.8% 7.71
Fibonacci 50% 6.57
Fibonacci 38.2% 5.43
Last Price 5.38
52-Week Low 1.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar